We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Alan Bryce

Alan H. Bryce MD

Chair, Division of Hematology/Oncology, Department of Internal Medicine, Mayo Clinic; Associate Professor of Medicine, Mayo Clinic College of Medicine and Science, Phoenix, Arizona

Alan H. Bryce, MD, is a consultant in the Division of Hematology and Oncology, Department of Internal Medicine at Mayo Clinic in Arizona and serves as chair of the division. He is also chair of the Genitourinary Disease Group. He holds the academic rank of associate professor of medicine, Mayo Clinic College of Medicine. He joined the staff of Mayo Clinic in 2011.

Dr. Bryce earned his B.S. degree in biochemistry at the University of California, Los Angeles, and his MD degree at Finch University of Health Sciences, Chicago Medical School. He completed a residency in internal medicine and a fellowship and chief fellowship in hematology/oncology at Mayo Graduate School of Medicine.

Dr. Bryce's primary focus in on prostate cancer and testicular cancer. His research centers on developing new approaches to the treatment and cure of cancer. This includes developing new treatments through clinical trials and better understanding of cancer evolution through interrogation of the genetic mutations of individual cancer cells. His work includes studies of immunotherapy, genetically targeted therapies, hormone therapy, injectable radiotherapy, and chemotherapy. Dr. Bryce is committed to health equity and patient centered care. He believes that individualized medicine starts with tailoring all treatment to the patient’s goals and values.